FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Zinda Michael					2. Issuer Name and Ticker or Trading Symbol Repare Therapeutics Inc. [RPTX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					wner
(Last)	•	rst) (I	Middle)		3. Date of Earliest Transa 03/28/2024				action (Month/Day/Year)					X Officer (give title Other (specify below) EVP, CHIEF SCIENTIFIC OFFICER					
(Street) ST-LAU (City)	Street) ST-LAURENT A8 H4S 1Z9				4. If Amendment, Date of Original Filed (Month/Day/Year) Rule 10b5-1(c) Transaction Indication								6. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				Execution Da		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			, 4 and Secur Benef		cially I Following	Forr (D) (m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) (D)	or Pric	е	Transa	saction(s) r. 3 and 4)			(111511. 4)	
Common Shares 03/28/				03/28/2	2024		S ⁽¹⁾		450	D	D \$4.64 ⁽²⁾		2) 72,318			D			
Common Shares 04/01/			04/01/2	2024			S ⁽¹⁾		410	D	\$4.	66(3)	71,908		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any		on Date, Transaction Code (Instr.		of Deriv Secu Acqu (A) o Dispo of (D (Instr	5. Number of Expiration Day (Month/Day/N Securities Acquired A) or Disposed of (D) (Instr. 3, 4 and 5)			ite	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der Sec (Ins	rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	(A) (D)		Date Exercisable		Expiration Date	Numbe of Title Shares									

Explanation of Responses:

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 24,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 8,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.38 to \$4.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.53 to \$4.76 inclusive.

/s/ Steve Forte, Attorney-in-

Fact ** Signature of Reporting Person Date

04/01/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.